{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:39:49Z","timestamp":1788316789869,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10067-018-4092-4","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T12:34:09Z","timestamp":1524054849000},"page":"1715-1720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Predictors of sustained clinical response in patients with Beh\u00e7et\u2019s disease-related uveitis treated with infliximab and adalimumab"],"prefix":"10.1007","volume":"37","author":[{"given":"Claudia","family":"Fabiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Vannozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"di Scala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Capozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"4092_CR1","unstructured":"Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V (2017) One year in review 2017: Beh\u00e7et\u2019s syndrome. Clin Exp Rheumatol"},{"key":"4092_CR2","first-page":"171","volume":"18","author":"A Vitale","year":"2016","unstructured":"Vitale A, Rigante D, Lopalco G, Selmi C, Galeazzi M, Iannone F, Cantarini L (2016) Interleukin-1 inhibition in Beh\u00e7et\u2019s disease. Isr Med Assoc J 18:171\u2013176","journal-title":"Isr Med Assoc J"},{"key":"4092_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/1744666X.2016.1205486","volume":"13","author":"F Davatchi","year":"2017","unstructured":"Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Sadeghi Abdollahi B, Ashofteh F, Mohtasham N, Kavosi H, Masoumi M (2017) Behcet\u2019s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol 13:57\u201365. \n                    https:\/\/doi.org\/10.1080\/1744666X.2016.1205486","journal-title":"Expert Rev Clin Immunol"},{"key":"4092_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12969-017-0162-4","volume":"15","author":"S Valenti","year":"2017","unstructured":"Valenti S, Gallizzi R, De Vivo D, Romano C (2017) Intestinal Beh\u00e7et and Crohn\u2019s disease: two sides of the same coin. Pediatr Rheumatol Online J 15:33. \n                    https:\/\/doi.org\/10.1186\/s12969-017-0162-4.","journal-title":"Pediatr Rheumatol Online J"},{"key":"4092_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.berh.2016.08.002","volume":"30","author":"E Seyahi","year":"2016","unstructured":"Seyahi E (2016) Beh\u00e7et\u2019s disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol 30:279\u2013295. \n                    https:\/\/doi.org\/10.1016\/j.berh.2016.08.002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4092_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/BOR.0000000000000349","volume":"29","author":"P Leccese","year":"2017","unstructured":"Leccese P, Yazici Y, Olivieri I (2017) Behcet\u2019s syndrome in nonendemic regions. Curr Opin Rheumatol 29:12\u201316","journal-title":"Curr Opin Rheumatol"},{"key":"4092_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","volume":"82","author":"E Kural-Seyahi","year":"2003","unstructured":"Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H (2003) The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60\u201376","journal-title":"Medicine (Baltimore)"},{"key":"4092_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol 138:373\u2013380. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2004.03.022","journal-title":"Am J Ophthalmol"},{"key":"4092_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11739-017-1691-z","volume":"12","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Orlando I, Sota J, Capozzoli M, Franceschini R, Galeazzi M, Tosi GM, Frediani B, Cantarini L (2017) Quality of life impairment in Beh\u00e7et\u2019s disease and relationship with disease activity: a prospective study. Intern Emerg Med 12:947\u2013955","journal-title":"Intern Emerg Med"},{"key":"4092_CR10","first-page":"478","volume":"19","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Orlando I, Capozzoli M, Fusco F, Rana F, Franceschini R, Sota J, Frediani B, Galeazzi M, Marco Tosi G, Cantarini L (2017) Impact of uveitis on quality of life: a prospective study from a tertiary referral rheumatology-ophthalmology collaborative uveitis center in Italy. Isr Med Assoc J 19:478\u2013483","journal-title":"Isr Med Assoc J"},{"key":"4092_CR11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10067-006-0484-y","volume":"26","author":"FS Neves","year":"2007","unstructured":"Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gon\u00e7alves CR (2007) Cross-cultural adaptation of the Beh\u00e7et\u2019s Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol 26:1263\u20131267. \n                    https:\/\/doi.org\/10.1007\/s10067-006-0484-y","journal-title":"Clin Rheumatol"},{"key":"4092_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/annrheumdis-2016-eular.5973","volume":"75","author":"Y Ozguler","year":"2016","unstructured":"Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Olivieri I, Yazici H, Hatemi G (2016) A systematic literature review on the treatment of major organ involvement of Beh\u00e7et\u2019s syndrome informing the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome. Ann Rheum Dis 75:800. [Poster presentation]. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-eular.5973","journal-title":"Ann Rheum Dis"},{"key":"4092_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41:61\u201370. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2010.09.002","journal-title":"Semin Arthritis Rheum"},{"key":"4092_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D, Network FB (2015) Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients. J Autoimmun 62:67\u201374. \n                    https:\/\/doi.org\/10.1016\/j.jaut.2015.06.005","journal-title":"J Autoimmun"},{"key":"4092_CR15","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","volume":"121","author":"M Takeuchi","year":"2014","unstructured":"Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, Maruyama K, Nakai K, Hijioka K, Shibuya E, Komae K, Hori J, Ohguro N, Sonoda KH, Mizuki N, Okada AA, Ishibashi T, Goto H, Mochizuki M (2014) Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et\u2019s disease: a multicenter study. Ophthalmology 121:1877\u20131884. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.042","journal-title":"Ophthalmology"},{"key":"4092_CR16","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, G\u00fcl A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum 52:2478\u20132484. \n                    https:\/\/doi.org\/10.1002\/art.21231","journal-title":"Arthritis Rheum"},{"key":"4092_CR17","doi-asserted-by":"publisher","unstructured":"Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Venerito V, Orlando I, Franceschini R, Fusco F, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Ten-year retention rate of infliximab in patients with Beh\u00e7et\u2019s disease-related uveitis. Ocul Immunol Inflamm:1\u20136. \n                    https:\/\/doi.org\/10.1080\/09273948.2017.1391297","DOI":"10.1080\/09273948.2017.1391297"},{"key":"4092_CR18","doi-asserted-by":"publisher","unstructured":"Fabiani C, Sota J, Vitale A, Rigante D, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Gentileschi S, Capozzoli M, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2017) Cumulative retention rate of adalimumab in patients with Beh\u00e7et\u2019s disease-related uveitis: a four-year follow-up study. Br J Ophthalmol. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310733","DOI":"10.1136\/bjophthalmol-2017-310733"},{"key":"4092_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","volume":"36","author":"C Fabiani","year":"2017","unstructured":"Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, Orlando I, Franceschini R, Bacherini D, Cimino L, Soriano A, Frediani B, Galeazzi M, Iannone F, Tosi GM, Salvarani C, Cantarini L (2017) Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36:183\u2013189. \n                    https:\/\/doi.org\/10.1007\/s10067-016-3480-x","journal-title":"Clin Rheumatol"},{"key":"4092_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C, Urban ML, Frediani B, Galeazzi M, Iannone F, Rigante D, Cantarini L (2017) Adalimumab effectiveness in Beh\u00e7et\u2019s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36:451\u2013455. \n                    https:\/\/doi.org\/10.1007\/s10067-016-3417-4","journal-title":"Clin Rheumatol"},{"key":"4092_CR21","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease (1990) Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"4092_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","unstructured":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD) (2014) The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338\u2013347. \n                    https:\/\/doi.org\/10.1111\/jdv.12107","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4092_CR23","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H (2005) Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study. J Rheumatol 32:98\u2013105","journal-title":"J Rheumatol"},{"key":"4092_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1177\/039463201002300303","volume":"23","author":"L Cantarini","year":"2010","unstructured":"Cantarini L, Rigante D, Lucherini OM, Cimaz R, Laghi Pasini F, Baldari CT, Benucci M, Simonini G, Di Sabatino V, Brizi MG, Galeazzi M (2010) Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 23:701\u2013707","journal-title":"Int J Immunopathol Pharmacol"},{"key":"4092_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00296-009-1322-8","volume":"32","author":"HM Shendi","year":"2012","unstructured":"Shendi HM, Walsh D, Edgar JD (2012) Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome. Rheumatol Int 32:249\u2013251. \n                    https:\/\/doi.org\/10.1007\/s00296-009-1322-8","journal-title":"Rheumatol Int"},{"key":"4092_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/03009740310003974","volume":"32","author":"G Federico","year":"2003","unstructured":"Federico G, Rigante D, Pugliese AL, Ranno O, Catania S, Stabile A (2003) Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular (CINCA) syndrome. Scand J Rheumatol 32:312\u2013314","journal-title":"Scand J Rheumatol"},{"key":"4092_CR27","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.autrev.2014.08.010","volume":"13","author":"F Caso","year":"2014","unstructured":"Caso F, Costa L, Rigante D, Vitale A, Cimaz R, Lucherini OM, Sfriso P, Verrecchia E, Tognon S, Bascherini V, Galeazzi M, Punzi L, Cantarini L (2014) Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev 13:1220\u20131229. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2014.08.010","journal-title":"Autoimmun Rev"},{"key":"4092_CR28","doi-asserted-by":"publisher","unstructured":"Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, Franceschini R, Bacherini D, Frediani B, Galeazzi M, Tosi GM, Cantarini L (2017) Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm:1\u20136. \n                    https:\/\/doi.org\/10.1080\/09273948.2017.1351573","DOI":"10.1080\/09273948.2017.1351573"},{"key":"4092_CR29","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s10067-017-3627-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G, Fabiani C, Gentileschi S, Silvestri E, Gerardo DS, Iannone F, Frediani B, Galeazzi M, Lapadula G, Rigante D, Cantarini L (2017) Long-term efficacy and safety of golimumab in the treatment of multirefractory Beh\u00e7et\u2019s disease. Clin Rheumatol 36:2063\u20132069. \n                    https:\/\/doi.org\/10.1007\/s10067-017-3627-4","journal-title":"Clin Rheumatol"},{"key":"4092_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785\u201396.e3. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2013.09.048","journal-title":"Ophthalmology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4092-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4092-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4092-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T19:20:21Z","timestamp":1555528821000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4092-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["4092"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4092-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"15 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}